Regorafenib, in particular, has demonstrated anti-immunosuppressive properties as well as antitumor immunity promotion by regulating macrophages and boosting proliferation and activation of CD8+ T-cells, and cabozantinib has a complementary effect with immune checkpoint inhibitors by acting on TAMs and reducing tumor vascularity [154]. The gene discussed is CD8A; the disease is neoplasm.